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Abstract 
Glycosphingolipids (GSL) are components of the outer leaflet of the plasma membrane (PM) of vertebrate tissues. Our current knowledge of GSL 
metabolism and their intracellular traffic has been derived from metabolic studies but the exact mechanisms by which GSLs are transported from 
sites of synthesis (endoplasmic reticulum and Golgi) to the sites of residence (PM) and degradation (lysosomes) have not been clearly defined. It is 
now established that components of the PM reach the lysosomal compartment mainly by endocytic membrane flow. According to a new model, GSLs 
derived from the PM are thought to end up in intra-endosomal vesicles which could be delivered, by successive processes of membrane fission and 
fusion, along the endocytic pathway directly into the lumen of the lysosomes. Here the GSLs are degraded in a step-wise manner by exohydrolases. 
However, the catabolism of membrane-bound GSLs with short hydrophilic head groups needs the assistance of sphingolipid activator proteins (SAPS), 
which lift the GSLs from the plane of the membrane and present hem for degradation to the lysosomal exohydrolases, which are usually water-soluble. 
The inherited deficiency of one of these enzymes or SAPS causes the lysosomal storage of their respective GSL substrates. In the case of the 
simultaneous deficiency of all 4 different SAPS the storage of all GSLs with short hydrophilic head groups occurs within multivesicular bodies and/or 
intra-lysosomal vesicles. 
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1. Topology of biosynthesis of glycosphingolipids 
Glycosphingolipids (GSL) are amphiphilic compo- 
nents of the PM characteristic of vertebrate tissues [l-3]. 
On the cell surface, different GSL structures form cell 
type- and differentiation-specific patterns. These pat- 
terns change with viral transformation and oncogenesis 
(see [4,5] for reviews). 
Our current knowledge of GSL biosynthesis and their 
intracellular traffic has been derived from metabolic 
studies. The mechanism by which GSLs are transported 
from sites of synthesis to other membranes has not been 
well defined. It was generally assumed [6,7] that GSL 
formation is coupled, as is the formation of glycopro- 
teins, to a vesicular membrane flow from the endoplas- 
mic reticulum (ER) through the cistemae of the Golgi 
complex to the PM (see [8] for review). However, the 
involvement of glycolipid binding and/or transfer pro- 
teins in the transport of GSL cannot be excluded. The 
role of several such proteins has not been identified 
1% 101. 
Glycosphingolipid biosynthesis starts with the con- 
densation of serine and pahnitoyl-CoA, yielding 3-keto- 
sphinganine [l I]. This ketone-derivative is rapidly re- 
*Corresponding author. Fax: (49) (228) 737 778. 
Abbreviations: GSL, glycosphingolipid; SAP, sphingolipid activator 
protein; PM, plasma membrane; ER, endoplasmic reticulum. 
duced to sphinganine by an NADPH-dependent reduc- 
tase [12]. The introduction of the 4-tram double bond 
occurs after addition of an amide-linked fatty acid (see 
[ 131 for review). Thus sphingosine is not an intermediate 
of the de novo biosynthetic pathway for ceramide. 
All enzymatic steps involved in the biosynthesis of 
ceramide appear to be located on the cytosolic face of the 
ER [14]. 
The next step in the biosynthesis of GSLs and sialyl- 
ated GSLs (gangliosides), namely the glucosylation of 
ceramide, is localized on the cytosolic side of Golgi mem- 
branes [15,16]. The following step, i.e. the formation of 
lactosylceramide (LacCer), a common precursor of most 
glycosphingolipid families, has presumably a luminal to- 
pology. 
The sequential addition of monosaccharide or sialic 
acid residues to the growing oligosaccharide chain, yield- 
ing ganglioside GM3 and successively more complex 
gangliosides, is catalyzed by membrane-bound glyco- 
syltransferases which have been shown to be restricted 
to the luminal surface of the Golgi apparatus (see [S] for 
review). A transfer of glucosylceramide (GlcCer) from 
the cytosolic to the luminal side of the Golgi membranes 
is therefore required but its occurrence has not been 
experimentally proven. 
Recent studies demonstrated that transfer of the same 
sugar residue to analogous glycolipid acceptors, differing 
only in the number of neuraminic acid residues bound 
to the inner galactose of the oligosaccharide chain, is 
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catalyzed by one and the same glycosyltransferase in rat 
liver Golgi (see [13] for review). 
2. Topology and mechanism of lysosomal glycolipid 
degradation role of sphingolipid activator proteins 
Components and fragments of the PM reach the lyso- 
somal compartment mainly by an endocytic membrane 
flow via the early and late endocytic reticulum [ 171. Dur- 
ing this vesicular flow, molecules in the membrane are 
subjected to a sorting process which directs some of the 
molecules to the lysosomal compartment, some others to 
the Golgi and yet others even back to the PM [l&21]. 
It remains, however, an open question whether compo- 
nents of the PM are included as components of the lyso- 
somal membrane after successive steps of vesicle bud- 
ding and fusion along the endocytotic pathway. We 
think that it is quite unlikely that the portion of the 
lysosomal membrane originating from the PM should be 
more or less selectively degraded by the lysosomal en- 
zymes. 
On the other hand, the observation of multivesicular 
bodies at the level of the early and late endosomal retic- 
ulum [21-241 suggests that parts of the endosomal mem- 
branes (possibly those enriched in components derived 
from the PM) bud off into the endosomal lumen and thus 
form intra-endosomal vesicles. These vesicles, enriched 
in PM components, could be delivered by successive 
processes of membrane fission and fusion along the en- 
docytic pathways, directly into the lysosol for final deg- 
radation of their components (Fig. 1). Thus glycoconju- 
gates, originating from the outer leaflet of the PM, would 
enter the lysosol seated on the outer leaflet of endocytic 
vesicles, facing the digestive juice of the lysosomes. This 
hypothesis [25] is supported by the accumulation of mul- 
tivesicular storage bodies in cells, e.g. Kupffer cells and 
fibroblasts, of patients with a complete deficiency of the 
sap-precursor protein with a combined activator protein 
deficiency [26,27], as well as by the observation that the 
epidermal growth factor receptor derived from the PM 
and internalized into lysosomes of hepatocytes is not 
integrated into the lysosomal membrane [28]. This view 
[25] is in accordance with recent observations by van 
Deurs et al. [29] who found that spherical multivesicular 
bodies were the predominant endocytic compartments in 
HEp-2 cells and that multivesicular bodies matured 
within 60-90 min into lysosomes till containing internal 
vesicles. 
It is not yet clear whether the early endosomes are 
gradually transformed to late endosomes and then to 
lysosomes. This would require the addition of several 
typical components for each organelle to the transform- 
ing and maturing compartment [30,31]. It is also possible 
that early endosomes, late endosomes and lysosomes al- 
ready exist and that intra-endosomal carrier vesicles are 
EGFR 
$11 Q PM 
- 
endosome 
/ ~ primary”, 
temporal 
fusion and 
discharge 
maturation , ’ 
glycocalix / 
lysosome 
Fig. 1. A new model for the topology of endocytosis and lysosomal 
digestion of GSLs derived from the plasma membrane (modified from 
[25]). During endocytosis glycolipids of the plasma membrane are sup- 
posed to end up in intra-endosomal vesicles (multivesicular bodies) 
from where they are discharged into the lysosomal compartment. GSL, 
glycosphingolipid; PM, plasma membrane; EGFR, epidermal growth 
factor receptor; 1 , glycolipid; -+, proposed pathway of endocytosis of 
GSL derived from the plasma membrane into the lysosomal compart- 
ment; - - ->, other intracellular outes for GSL derived from the plasma 
membrane. 
transported successively from one compartment o an- 
other. Recently Mullock and Luzio [32] proved the asso- 
ciation and fusion from endosomes with pre-existing ly- 
sosomes in a cell-free preparation from rat liver. Since 
the experimental conditions did not permit the matura- 
tion of endosomes to lysosomes, the results must indicate 
some vesicular transport between pre-existing compart- 
ments. 
Finally, components of the PM reaching the lysosomes 
are digested by a mixture of hydrolases most active in the 
acidic environment of the lysosol. On the other hand, 
lysosomal membranes hould be protected against pre- 
mature digestion. This is accomplished by a massive gly- 
cocalix formed on the inner surface of the lysosomal 
membrane by the extended carbohydrate moiety of the 
LIMPS (lysosomal integral membrane proteins) and 
LAMPS (lysosomal associated membrane proteins) con- 
stituting the lysosomal membranes [33]. 
Degradation of GSL occurs by step-wise action of 
specific acid exohydrolases. Several of these enzymes 
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Fig. 2 Model for the GMZactivator stimulated egradation of ganglioside GM2 by human hexosamimdase A (modified from [25]). Water-soluble 
hexosaminidase A does not degrade membrane-bound ganglioside GM2, which has a short carbohydrate chain, in the absence of GM2-activator 
or appropriate detergents. However, it degrades ganglioside GDla-GalNAc, which has an extended carbohydrate chain, and also analogues of 
ganglioside GM2, which contain a short acyl residue or no acyl residue (lysoganglioside GM2). They are less firmly bound to the lipid bilayer and 
more water-soluble than GM2. Ganghoside GM2 bound to a lipid-bilayer, e.g. of an intra-lysosomal vesicle (see Fig. 1) is hydrolyzed in the presence 
of the GMZ-activator. The GMZ-activator binds one ganglioside GM2 molecule and lifts it a few A out of the membrane. This activator-lipid complex 
can be reached and recognized by water-soluble hexosaminidase A which cleaves the substrate (mode 1). It is, however, also possible that the 
water-soluble activator-lipid complex leaves the membrane and that the enzymatic reaction takes place in free solution (mode 2). The terminal 
GalNAc residue of membrane-incorporated ganghoside GDla-GalNAc protrudes from the membrane far enough to be accessible to hexosaminidase 
A without an activator. 
need the assistance of small glycoprotein cofactors, the 
so-called SAPS [25], when they attack membrane- or ves- 
icle-bound GSL substrates with short oligosaccharide 
head groups. 
Since the discovery of sulphatide activator protein 
[34], several other factors have been described but their 
identity, specificity and function have remained unclear. 
When sequence data became available it turned out that 
only two genes code for the five SAPS known [25]. One 
gene carries the genetic information for the GM2-activa- 
tor and the other for the sap-precursor, which is proc- 
essed to four homologuous proteins, including sulfatide 
activator protein (sap-B) and glucosylceramidase activa- 
tor protein (sup-c). 
A range of experimental data [35] suggests a mecha- 
nism of action for the GMZactivator. Hexosaminidase 
A is a water-soluble nzyme which acts on substrates of 
the membrane surface only if they extend far enough into 
the aqueous phase (Fig. 2). Like a razor blade or a lawn- 
mower the enzyme recognizes and cleaves all substrates 
(e.g. GDla-GalNAc) which stick out far enough into the 
aqueous space. Those GSL substrates with oligosac- 
charide head groups too short to be reached by the 
water-soluble enzyme, however, cannot be degraded. 
Their degradation requires a second component, the 
GM2-activator, a specialized GSL-binding protein, 
which complexes the substrate (e.g. ganglioside GM2), 
lifting and even extracting it from the membrane and 
presenting it to the hexosaminidase A for degradation. 
While GMZactivator (a liftase) and hexosaminidase A
(a lawn-mower) represent selective and precisely tuned 
machinery for the degradation of a few structurally sim- 
ilar membrane-bound sphingolipids, sup-B stimulates 
the degradation of many lipids by several enzymes from 
human, plant and even bacterial origin [36]. Thus sap-B 
seems to act as a kind of physiological detergent with 
broad specificity and solubilizes glycolipid substrates 
[37l. 
Unlike GMZactivator and sup-B, sup-C is reported to 
form complexes with membrane-associated nzymes and 
apparently activates them [38-41]. 
In summary, GSLs with short hydrophilic head 
groups are degraded by a two-component system: an 
enzyme and an activator protein. This seems to be much 
safer for the stability of short-chain GSLs outside the 
lysosomal compartment, e.g. on the cell surface. 
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Fig. 3 Structure of the sap-precursor cDNA (according to [25], supplemented by a further mutation). The cDNA ofsap-precursor codes for a sequence 
of 524 amino acids (or of 527 amino acids, see [51]) including a signal peptide of 16 amino acids (termed s, for the entry into the ER) [25,54]. The 
four domains on the precursor, termed saposins A-D by O’Brien et al. [46], correspond to the mature proteins found in human tissues: A, sap-A 
or saposin A; B, sap-B or saposin B or SAP-1 or sulfatide-activator; C, sap-C or SAP-2 or saposin C or glucosylceramidase activator protein; D, 
sap-D or saposin D or component C. The positions of cysteine residues are marked by vertical bars and those of the N-glycosylation sites by arrow 
heads. The positions of the 14 introns and of the known mutations leading to diseases are also given: (a) Al-tT (Met’+Leu) [271; (b) C650-+T 
(Th?“-+Ile) [47,48]; (c) 33 bp insertion after G777 (11 additional amino acids after Met25p [49,50]; (d) G722+C (Cys”‘+Ser) [51]; (e) Gl154+T 
(Cys”‘+Phe) [52]; (f) T1155-1G (Cy~~~‘--+Gly) [53]. 
3. Pathobiochemistry of inherited enzyme and activator 
protein deficiencies 
As already mentioned, the final degradation of sphin- 
golipids occurs in the lysosome. Here they are degraded 
in a step-wise manner starting at the hydrophilic end of 
the molecule by exohydrolases. The inherited deficiency 
of one or the other of these enzymes causes the lysosomal 
storage of the respective substrates. The diseases result- 
ing from these defects are rather heterogeneous from the 
biochemical as well as from the clinical point of view (see 
[42] for review). 
The analysis of sphingolipid storage diseases without 
detectable hydrolase deficiency resulted in the identifica- 
tion of several point mutations in the GMZactivator 
gene (see [25] for review) and in the sup-precursor gene 
(Fig. 3). Interestingly, mutations affecting the sup-C do- 
main (Gaucher factor) resulted in a variant form of 
Gaucher disease and mutations affecting the sap-B do- 
main (sulfatide activator) resulted in variant forms of 
metachromatic leukodystrophy. On the other hand, a 
mutation in the start codon, ATG, of the sap-precursor 
resulted in a defect of the sap-precursor, SAPS A, B, C, 
D, and also in a simultaneous torage of ceramide and 
GSLs with short oligosaccharide head groups, such as 
glucosylceramide, lactosylceramide, galactosylceramide, 
sulphatide and ganglioside GM3 in the patients’ tissue 
[26,43&I]. As detected by electron microscopy storage 
occurs predominantly within multivesicular bodies and/ 
or within intra-lysosomal vesicles [44]. Obviously in the 
absence of the four SAPS, GSLs with short carbohydrate 
chains are not degraded. This also stabilizes the intra- 
lysosomal vesicles against degradation by lysosomal en- 
zymes. This observation also suggests another distinct 
function that GSLs and other glycoconjugates may have 
on PMs; they may protect cell surfaces against premature 
digestion by extracellular hydrolases, e.g. phospholi- 
pases. Bianco reported that a molar fraction of 0.2 or 
more of ganglioside GM1 in the lipid monolayer com- 
pletely protects the phospholipids in those monolayers 
against digestion by phospholipase A2 from pig pancreas 
[451. 
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